RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsOctober 24, 2023 - AstraZenecas Enhertu associated with patient deaths reported at ESMO
In the lung cancer study, the pharma partners reported seven fatal episodes of interstitial lung disease (ILD), which were “adjudicated as drug-related by an independent committee,” according to the announcement. In four of these deaths, the primary cause was attributed to disease progression. One such fatality was reported in the comparator docetaxel group.
In terms of efficacy, Dato-DXd cut the risk of disease progression or death by 25% versus docetaxel in the lung cancer study, with a median progression-free survival (PFS) of 4.4 months compared to 3.7 months in the control group.
Dato-DXd’s PFS benefit (6.9 monts) was slightly better in the breast cancer study, reducing the risk of progression or death by 37% compared with the investigator’s choice of chemotherapy.
https://www.onclive.com/view/datopotamab-deruxtecan-provides-pfs-benefit-in-hr-her2-breast-cancer
“Datopotamab deruxtecan is central to the future we envision where antibody drug conjugates improve upon and ultimately displace entrenched standards of care, like chemotherapy, in multiple cancer types,” Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca, said in a statement. These findings from TROPION-Lung01 and TROPION-Breast01 will help the companies build their case for using Dato-DXd in these indications.
[ ONCYs pelareorep is seeking to further improve upon and ultimately displace entrenched standards of care. ]
https://www.biospace.com/article/astrazeneca-daiichi-address-safety-and-survival-of-dxd-adc-at-esmo/